# Andrew Elder

> Andrew Elder is a Series A investor at AlbionVC (London) backing Health Care and Medical. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [AlbionVC](https://shizune.co/investors/profile/albion-vc)
- Location: London, United Kingdom
- Total investments: 8
- Last investment: Nov 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/andrew-elder-6318412/

Andrew Elder is a Series A investor at AlbionVC in London focused on Health Care and Medical. Andrew initially qualified as a surgeon from Cambridge University. He practiced for six years, specialising in neurosurgery, before joining the Boston Consulting Group (BCG) as a consultant in 2001. Whilst at BCG he specialised in healthcare strategy, gaining experience with many large, global clients across the full spectrum of healthcareincluding biotechnology, pharmaceuticals, service and care providers, software and telecommunications. He joined Close Ventures in 2005. Andrew became a partner in Albion Ventures in 2009.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 38% |
| Medical | 2 | 25% |
| Hospital | 1 | 13% |
| Software | 1 | 13% |
| Automotive | 1 | 13% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Funding Round | 3 | 38% |
| Series B | 2 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 3 | 38% |
| United States | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Healios | Founded in 2013, Healios is a leading digital healthcare technology company working to empower patients and families affected by mental and physical illnesses.Healios is pioneering how family intervention and behavioural change techniques are delivered beyond treatment team walls, to maximise patient and family outcomes. By blending the best oftechnology, specialised expertise and a personal human connection, they help patients and families develop a new level of understanding and sustain healthier habits over time. Their mission is to transform how care is delivered to help patients, families and carers effectively move forward and achieve their goals, providing a better quality of life. | $15.6M | Series B | Nov 03, 2022 |  |
| Neurofenix | Aiming to make rehabilitation more autonomous, enjoyable and accessible to stroke victims. | $6.9M | Series A | Aug 29, 2022 |  |
| uMotif | UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceuticalcompanies to capture rich health data across a range of conditions. | $25.2M | Series B | May 25, 2022 |  |
| Healios | Founded in 2013, Healios is a leading digital healthcare technology company working to empower patients and families affected by mental and physical illnesses.Healios is pioneering how family intervention and behavioural change techniques are delivered beyond treatment team walls, to maximise patient and family outcomes. By blending the best oftechnology, specialised expertise and a personal human connection, they help patients and families develop a new level of understanding and sustain healthier habits over time. Their mission is to transform how care is delivered to help patients, families and carers effectively move forward and achieve their goals, providing a better quality of life. | $9.9M | Series A | May 18, 2021 |  |
| uMotif | UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceuticalcompanies to capture rich health data across a range of conditions. | $6.6M | Series A | Sep 03, 2020 |  |
| Healios | Founded in 2013, Healios is a leading digital healthcare technology company working to empower patients and families affected by mental and physical illnesses.Healios is pioneering how family intervention and behavioural change techniques are delivered beyond treatment team walls, to maximise patient and family outcomes. By blending the best oftechnology, specialised expertise and a personal human connection, they help patients and families develop a new level of understanding and sustain healthier habits over time. Their mission is to transform how care is delivered to help patients, families and carers effectively move forward and achieve their goals, providing a better quality of life. | $2.9M |  | Jun 14, 2018 |  |
| uMotif | UMotif is a scalable and engaging patient-centred data capture platform for modern research. The platform provides patient-facing technology to capture data for clinical research initiatives and also captures compliant, validated patient-generated e-consent, eCOA, ePRO, PROM, and PREM data for researchers and clinicians, allowing pharmaceuticalcompanies to capture rich health data across a range of conditions. | $3.1M |  |  |  |
| Masters Pharmaceutical | Masters Pharmaceutical is a pharmaceuticals company offering pharmaceutical and medical products. | $3.4M |  |  |  |

8 of 8 investments shown.

## Co-investors
- [InHealth Ventures](https://shizune.co/investors/profile/inhealth-ventures) — VC Fund, 5 deals together
- [DNV GL](https://shizune.co/investors/profile/dnv-gl) — VC Fund, 2 deals together
- [Athyrium Capital Management LP](https://shizune.co/investors/profile/athyrium-capital-management) — VC Fund, 1 deal together
- [Autism Impact Fund](https://shizune.co/investors/profile/autism-impact-fund) — VC Fund, 1 deal together
- [HTH](https://shizune.co/investors/profile/hth) — VC Fund, 1 deal together
- [Spice Capital Partners](https://shizune.co/investors/profile/oteo-investment) — VC Fund, 1 deal together

## About AlbionVC

VC Fund · London, United Kingdom

AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/

5 contacts available at AlbionVC.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Chirkowski | Partner | https://shizune.co/investors/profile/adam-chirkowski |
| Christoph Ruedig | Partner | https://shizune.co/investors/profile/christoph-ruedig |
| Ed Lascelles | Partner | https://shizune.co/investors/profile/ed-lascelles |
| Andrew Elder | Deputy Managing Partner | https://shizune.co/investors/profile/andrew-elder |
| Cat McDonald | Investment Manager | https://shizune.co/investors/profile/cat-mcdonald |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Andrew Elder invest in?

Andrew Elder invests primarily in Health Care, Medical and Hospital startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Elder last invest?

The most recent investment recorded for Andrew Elder closed in Nov 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co